The ability of midostaurin to synergize with dual FLT3/SYK inhibitors, R406 and R788, or the highly targeted SYK inhibitor, PRT062607, was tested in a panel of Ba/F3 cell lines expressing constitutively active SYK in the presence or absence of FLT3-ITD, as well as Ba/F3-FLT3-ITD cells and human AML lines, such as MOLM13-luc+, MOLM14, and MV4,11, driven by FLT3-ITD. Here, SYK is linked to acute myeloid leukemia.